Mark Coleman is Director at Axsome Therapeutics, Inc. (AXSM). They have made 8 open-market trades across 1 company since 2019, most recently 2026-06-10.
CIK 0001658379
7 open-market purchases totalling $929K since 2019, against 1 sale. Across 7 scored buys the stock is up 4.7% at ninety days, and 1.9 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AXSM | 30,389 | $4.8M |
Shares reported on the most recent Form 4, priced at the 2026-06-10 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 43% | 57% | 57% |
| Avg Move | -3.9% | +1.9% | +4.7% |
| Alpha | -4.3% | -0.5% | +1.9% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AXSM | SELL · 10b5-1 | 2026-06-10 | 2026-06-10 | $249.00 | $160K | -3.1% | -6.4% | -16.8% |
| AXSM | SELL · 10b5-1 | 2026-05-29 | 2026-06-02 | $229.20 | $4.0M | +13.7% | +8.8% | -11.6% |
| AXSM | SELL · 10b5-1 | 2026-02-26 | 2026-02-27 | $161.11 | $4.0M | -1.6% | -1.0% | +43.7% |
| AXSM | BUY | 2025-09-08 | 2025-09-09 | $127.31 | $263K | -9.5% | -4.3% | +15.2% |
| AXSM | SELL · 10b5-1 | 2025-05-27 | 2025-05-29 | $104.45 | $1.6M | +5.1% | -0.1% | +16.6% |
| AXSM | SELL | 2025-05-20 | 2025-05-20 | $107.49 | $322K | +0.4% | -6.1% | +3.6% |
| AXSM | SELL · 10b5-1 | 2024-05-28 | 2024-05-29 | $75.18 | $1.6M | -5.5% | +5.9% | +17.0% |
| AXSM | SELL · 10b5-1 | 2023-09-15 | 2023-09-15 | $75.18 | $4.4M | -2.9% | -10.1% | -1.5% |
| AXSM | BUY | 2021-11-18 | 2021-11-22 | $35.09 | $50K | -13.4% | +1.2% | -23.6% |
| AXSM | BUY | 2021-05-12 | 2021-05-13 | $58.15 | $29K | -10.1% | +11.1% | -60.6% |
| AXSM | BUY | 2020-06-29 | 2020-06-30 | $78.50 | $51K | -6.8% | -9.4% | -7.2% |
| AXSM | BUY | 2019-06-25 | 2019-06-27 | $23.10 | $374K | +1.6% | +3.4% | +4.3% |
| AXSM | BUY | 2019-05-13 | 2019-05-15 | $21.44 | $100K | +8.6% | -1.6% | +19.1% |
| AXSM | BUY | 2019-03-19 | 2019-03-21 | $12.18 | $62K | +2.3% | +13.0% | +85.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.